Published in Health Qual Life Outcomes on August 20, 2014
Psychometric properties of Patient Reported Outcome Measures (PROMs) in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). Health Qual Life Outcomes (2016) 0.77
Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas (2016) 0.75
Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res (2016) 0.75
The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Med (2015) 0.75
The St. George's Respiratory Questionnaire as a prognostic factor in IPF. Respir Res (2017) 0.75
Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. PLoS One (2017) 0.75
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 0.75
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
The St George's Respiratory Questionnaire. Respir Med (1991) 8.49
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
St. George's Respiratory Questionnaire: MCID. COPD (2005) 3.99
Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J (2002) 3.92
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med (2012) 2.36
Assessment of health-related quality of life in patients with interstitial lung disease. Chest (1999) 2.21
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev (2012) 1.94
Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes (2005) 1.69
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J (2006) 1.65
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax (2005) 1.64
Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med (2005) 1.51
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med (2013) 1.51
Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest (2005) 1.36
Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology (2008) 1.32
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med (2013) 1.21
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14
Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2013) 1.07
Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med (2005) 1.06
Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest (2013) 1.05
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil (2006) 1.04
Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest (2010) 1.04
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax (2012) 0.98
Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Int J Chron Obstruct Pulmon Dis (2011) 0.97
Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest (2013) 0.89
Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest (2012) 0.88
Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. Chest (2012) 0.86
Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients. Braz J Med Biol Res (2007) 0.83
An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition. Lung India (2011) 0.81
Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J (2011) 0.80
Cross-sectional and longitudinal construct validity of the Saint George's Respiratory Questionnaire in patients with IPF. Respirology (2008) 0.79
Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med (2013) 0.79
[Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis]. Rev Mal Respir (2009) 0.77
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med (2011) 2.62
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.50
Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 2.43
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med (2006) 2.34
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest (2002) 2.19
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest (2004) 2.00
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev (2012) 1.94
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med (2005) 1.90
Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest (2011) 1.85
A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology (2010) 1.80
The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One (2013) 1.78
Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax (2013) 1.77
Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest (2006) 1.76
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest (2008) 1.65
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest (2005) 1.60
Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD (2008) 1.59
Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One (2009) 1.56
Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD (2008) 1.55
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest (2007) 1.53
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest (2010) 1.52
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med (2013) 1.51
Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl Health Econ Health Policy (2014) 1.51
Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury. J Immunol (2007) 1.51
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest (2009) 1.50
Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol (2004) 1.50
Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest (2006) 1.48
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax (2009) 1.46
Open-access biorepository for idiopathic pulmonary fibrosis. The way forward. Ann Am Thorac Soc (2014) 1.42
Rheumatoid arthritis-related lung diseases: CT findings. Radiology (2004) 1.40
Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol (2011) 1.38
Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med (2009) 1.36
Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol (2009) 1.32
Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology (2011) 1.32
Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med (2005) 1.30
Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology (2008) 1.29
Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest (2007) 1.28
Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest (2014) 1.25
Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest (2004) 1.24
Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med (2012) 1.23
The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med (2004) 1.22
Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr (2002) 1.20
Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol (2005) 1.20
Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. Radiographics (2009) 1.18
TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis. Am J Respir Cell Mol Biol (2005) 1.17
Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med (2015) 1.15
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol (2010) 1.15
Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med (2005) 1.13
Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest (2013) 1.11
The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One (2012) 1.07
Human lung project: evaluating variance of gene expression in the human lung. Am J Respir Cell Mol Biol (2006) 1.07
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med (2013) 1.07
Challenges in pulmonary fibrosis. 3: Cystic lung disease. Thorax (2007) 1.05
Scleroderma lung disease. Eur Respir Rev (2013) 1.04
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest (2009) 1.03
Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest (2008) 1.02
Diffuse pulmonary neuroendocrine cell hyperplasia: radiologic and clinical features. J Comput Assist Tomogr (2002) 1.02
Collagen vascular disease-related lung disease: high-resolution computed tomography findings based on the pathologic classification. J Comput Assist Tomogr (2004) 1.01
Update in the diagnosis and management of pulmonary vasculitis. Chest (2006) 1.01
Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest (2014) 0.99
Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series. Chest (2008) 0.99
Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes (2010) 0.98
Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. Protein Sci (2004) 0.98
Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol (2006) 0.97